Current Report Filing (8-k)
September 21 2017 - 05:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of
Report: September 15, 2017
(Date of earliest event reported)
TENET HEALTHCARE CORPORATION
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Nevada
|
|
1-7293
|
|
95-2557091
|
(State of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
1445 Ross Avenue, Suite 1400
Dallas, Texas 75202
(Address of principal executive offices, including zip code)
(469)
893-2200
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the Registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this
chapter).
Emerging Growth Company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements Of Certain Officers.
|
On September 15, 2017, the Human Resources Committee (HR Committee) of the Board of Directors and the other independent
directors of Tenet Healthcare Corporation (the Company) approved the compensation arrangements of Ronald A. Rittenmeyer, who, as previously reported, was appointed as the Companys Executive Chairman on August 31, 2017. While
serving as Executive Chairman, Mr. Rittenmeyer will receive an annualized base salary of $500,000. In addition, Mr. Rittenmeyer will receive an award of performance-based stock options with a grant date fair value of approximately
$2.3 million. The stock options will vest on the
one-year
anniversary of the grant date (subject to accelerated vesting upon certain involuntary terminations of employment or change of control events) and
will become exercisable only if the average closing price per share of the Companys common stock is at least 25% above the closing price of the Companys stock as of the grant date within any 30 consecutive trading days during the first
four years following the grant date. If the stock price performance condition is not achieved by the fourth anniversary of the grant date, the entire option award will be forfeited at that time. The stock options will have a maximum term of five
years from the date of grant. The grant date will be the last trading day in September, in accordance with the Companys policy for equity grants awarded outside of the annual grant process cycle. Mr. Rittenmeyer will not participate in
the Companys Annual Incentive Plan and will not be covered by its Executive Severance Plan.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
TENET HEALTHCARE CORPORATION
|
|
|
By:
|
|
/s/ Paul A. Castanon
|
|
|
Paul A. Castanon
|
|
|
Vice President, Deputy General Counsel and Corporate Secretary
|
Date: September 21, 2017
3
Tenet Healthcare (NYSE:THC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Tenet Healthcare (NYSE:THC)
Historical Stock Chart
From Mar 2023 to Mar 2024